Discover how AI-driven pharmacovigilance uses machine learning, NLP, and advanced analytics to enhance adverse event detection, accelerate safety signal detection, and improve drug safety monitoring across complex, real-world data sources.
Learn what deucravacitinib is, how selective TYK2 inhibition works, and key clinical trial results in moderate-to-severe plaque psoriasis. Discover its mechanism, benefits over traditional JAK inhibitors, and potential role as an oral alternative to biologics.
Learn what AI-driven pharmacovigilance is and how machine learning, NLP, and advanced analytics are transforming drug safety signal detection, case processing, and real-world evidence analysis in a data-saturated healthcare landscape.
Learn what proteolysis-targeting chimeras (PROTACs) are, how they work as small-molecule protein degraders, and why they outperform classic inhibitors by accessing undruggable targets, driving deep protein knockdown, and enabling next-generation cancer therapies like ARV-110.
Discover how tirzepatide, a first‑in‑class dual GIP/GLP‑1 “twincretin,” delivers up to ~20% body weight reduction, improves cardiometabolic risk factors, and bridges the gap between obesity pharmacotherapy and metabolic surgery.
Discover how AI-powered pharmacovigilance uses machine learning, NLP, and real-world data to detect adverse drug reactions faster, enhance signal detection, and improve global drug safety monitoring.
Learn what xanomeline-trospium is, how its muscarinic M1/M4 receptor mechanism differs from dopamine-based antipsychotics, and review key phase 2 clinical trial data for schizophrenia and Alzheimer’s-related psychosis.
Discover how AI and machine learning are revolutionizing oral small molecule drug discovery—from target-informed data assembly and generative design to in silico ADME profiling—enabling faster, more selective, and orally bioavailable small-molecule therapies.
Discover how AI and machine learning are reshaping pharmacovigilance by scaling drug safety surveillance across EHRs, social media, wearables, and real‑world data. Learn key use cases, benefits, limitations, and compliance considerations for building trustworthy, regulatory‑aligned intelligent safety systems.
Discover how tirzepatide, a next‑generation dual GLP‑1/GIP agonist, delivers bariatric‑level weight loss, improves glycemic control, and sets a new standard for protein–peptide obesity drugs and metabolic disease management.